Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Otenaproxesul - Antibe Therapeutics

Next Previous
Drug Profile

Otenaproxesul - Antibe Therapeutics

Alternative Names: ATB-346

Latest Information Update: 18 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Antibe Therapeutics
  • Developer Antibe Therapeutics; Imperial College of Science, Technology and Medicine; McMaster University; Universita di Napoli Federico II; University of Calgary; William Harvey Research Institute
  • Class Analgesics; Anti-inflammatories; Antineoplastics; Antirheumatics; Esters; Naphthaleneacetic acids; Nonsteroidal anti-inflammatories; Small molecules; Vasodilators
  • Mechanism of Action Apoptosis stimulants; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Familial adenomatous polyposis

Highest Development Phases

  • Phase II Musculoskeletal pain
  • Phase I Postoperative pain
  • Clinical Phase Unknown Acute pain
  • Discontinued Intestinal cancer; Malignant melanoma; Periodontal disorders

Most Recent Events

  • 01 Apr 2024 Antibe Therapeutics supends phase II trial in Postoperative pain
  • 28 Mar 2024 The US FDA puts a clinical hold on otenaproxesul, postponing the initiation of the planned phase II trial
  • 04 Mar 2024 Abitrator finds in favor of Nuance Pharma in the dispute regarding the license agreement with Antibe Therapeutics regarding commercialization of otenaproxesul in the Greater China region, resulting in the termination of licensing agreement
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top